Locally Advanced Pancreatic Cancer: A Review

125I particle implantation combined with chemoradiotherapy to treat advanced pancreatic cancer

“…11 It is reported that approximately 40% of pancreatic cancer patients present with locally advanced, non-metastatic disease. 12 Local lesions play a vital role in a patient's survival. [13][14][15][16] The aim of advanced pancreatic cancer treatment is to enhance local lesion control and improve the quality of life (QOL).…”

Cancer Terminator Viruses and Approaches for Enhancing Therapeutic Outcomes

“…Based on difficulty in early diagnosis of pancreatic ductal adenocarcinoma (PDAC), this disease is often noticeable after metastasis has occurred and this is one of the reasons it has the shortest average survival time in contrast to all other cancer types (Bardeesy & DePinho, 2002; Jaffee, Hruban, Canto, & Kern, 2002; Russo, Butler, Ove, & Blackstock, 2007). Surgical resection remains the only viable choice for achieving a cure, but only 15–20% of patients, newly diagnosed with pancreatic cancer, are candidates for surgical resection and, regrettably, the majority of resections result in recurrent disease (Donahue & Reber, 2010).…”

Decoy Receptor 3 Expression in AsPC-1 Human Pancreatic Adenocarcinoma Cells via the Phosphatidylinositol 3-Kinase-, Akt-, and NF-κB-Dependent Pathway

“…This disease is usually diagnosed at a late, incurable stage, and the 5-year survival rate is less than 5% (22). Pancreatic cancer is relatively resistant to cytotoxic therapy (22) and radiation treatment (23). In addition, there is increasing evidence that many cancers, including pancreatic cancer, develop different methods of evading destruction by the immune system, such as resistance to FasL-Fas interaction-mediated apoptotic signals, despite expressing Fas (24).…”